Claims for Patent: 9,126,987

Summary for Patent: 9,126,987

Title:	Inhibitors of glutaminyl cyclase
Abstract:	The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, ##STR00001## wherein R.sup.1 represents heteroaryl, -carbocyclyl-heteroaryl, -alkenylheteroaryl or -alkylheteroaryl; R.sup.2 represents alkyl; carbocyclyl which may optionally be substituted by alkyl; alkenyl; alkynyl, provided a triple bond is not adjacent to X; -alkyl-aryl; -alkyl-heteroaryl; -alkyl-heterocyclyl in which heterocyclyl may optionally be substituted by alkyl; -alkyl-carbocyclyl in which carbocyclyl may optionally be substituted by alkyl; aryl; heteroaryl; or H; X represents S or NR.sup.3; R.sup.3 represents H or C.sub.1-4 alkyl.
Inventor(s):	Heiser; Ulrich (Halle/Saale, DE), Ramsbeck; Daniel (Halle/Saale, DE), Buchholz; Mirko (Halle, DE), Niestroj; Andre J. (Sennewitz, DE)
Assignee:	PROBIODRUG AG (Halle/Saale, DE)
Application Number:	11/946,101
Patent Claims:	1. A compound of formula (I), ##STR00043## wherein R.sup.1 represents benzimidazole; R.sup.2 represents alkyl; carbocyclyl which may optionally be substituted by alkyl; alkenyl; alkynyl, provided a triple bond is not adjacent to X; -alkyl-aryl which may optionally be substituted by alkyl, alkoxy, or halogen; -alkyl-carbocyclyl in which carbocyclyl may optionally be substituted by alkyl; or aryl which may optionally be substituted by alkyl, alkoxy, or halogen; wherein carbocyclyl is defined as a saturated or partially unsaturated one, two, or three carbon ring system comprising between three and twelve ring carbon atoms; X represents S or NR.sup.3; R.sup.3 represents H or C.sub.1-4 alkyl; or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof; with the proviso that the following compounds are excluded from the scope of formula (I): ##STR00044## 2. A compound according to claim 1 wherein R.sup.1 represents 1H-benzoimidazol-5-yl. 3. A compound according to claim 1 wherein R.sup.2 represents alkyl; alkenyl; -alkyl-aryl; or aryl. 4. A compound according to claim 3 wherein R.sup.2 represents alkenyl or -alkyl-aryl which may optionally be substituted by alkyl, alkoxy, or halogen. 5. A compound according to claim 4 wherein R.sup.2 represents -alkyl-aryl which may optionally be substituted by alkyl, alkoxy, or halogen. 6. A compound according to claim 5 wherein R.sup.2 represents benzyl. 7. A compound according to claim 1 wherein X represents S or NH. 8. A compound according to claim 7 wherein X represents S. 9. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of: 5-(5-(benzylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazole; 5-(5-(phenethylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazole; 5-(5-(3-phenylpropylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazole; 5-(5-((naphthalen-2-yl)methylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imida- zole; 5-(5-(methylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazole; 5-(5-(allylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazole; 5-(5-(ethylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazole; 5-(5-(octylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazole; 5-(5-(4-tert-butylbenzylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazole; 5-(5-(4-chlorobenzylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazole; 5-(5-(4-fluorobenzylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazole; 5-(5-(3,4,5-trifluorobenzylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazo- le; 5-(5-(Pentafluorobenzylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazol- e; 5-(5-(2,4,6 trimethylbenzylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazole; 5-(5-(2,3,4,5,6-pentamethylbenzylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]i- midazole; 5-(5-(3,4,5-trimethoxybenzylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo- [d]imidazole; 5-(1H-benzo[d]imidazol-5-yl)-N-(3,4-dimethoxyphenyl)-1,3,4-oxadiazol-2-am- ine; 5-(1H-benzo[d]imidazol-5-yl)-N-(4-chlorophenyl)-1,3,4-oxadiazol-2-ami- ne; 5-(1H-benzo[d]imidazol-5-yl)-N-(4-fluorophenyl)-1,3,4-oxadiazol-2-amin- e; N-(4-fluorobenzyl)-5-(1H-benzo[d]imidazol-5-yl)-1,3,4-oxadiazol-2-amine- ; 5-(5-(4-methylbenzylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazole; and 5-(1H-benzo[d]imidazol-5-yl)-N-benzyl-1,3,4-oxadiazol-2-amine. 10. A compound according to claim 9 or a pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of: 5-(5-(benzylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazole; 5-(5-(phenethylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazole; 5-(5-(3-phenylpropylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazole; 5-(5-((naphthalen-2-yl)methylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imida- zole; 5-(5-(allylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazole; 5-(5-(4-tert-butylbenzylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazole; 5-(5-(4-chlorobenzylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazole; 5-(5-(4-fluorobenzylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazole; 5-(5-(Pentafluorobenzylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazole; and 5-(5-(2,4,6 trimethylbenzylthio)-1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazole. 11. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 optionally in combination with one or more therapeutically acceptable diluents or carriers. 12. The pharmaceutical composition of claim 11, which further comprises at least one compound, selected from the group consisting of neuroprotectants, antiparkinsonian drugs, amyloid protein deposition inhibitors, beta amyloid synthesis inhibitors, antidepressants, anxiolytic drugs, antipsychotic drugs, and anti-multiple sclerosis drugs. 13. The pharmaceutical composition of claim 11, which further comprises at least one compound, selected from the group consisting of PEP-inhibitors, LiCI, inhibitors of dipeptidyl aminopeptidases, inhibitors of DP IV enzymes or DP IV-like enzymes, acetylcholinesterase (ACE) inhibitors, PIMT enhancers, inhibitors of beta secretases, inhibitors of gamma secretases, inhibitors of neutral endopeptidase, inhibitors of Phosphodiesterase-4 (PDE-4), TNF alpha inhibitors, muscarinic M1 receptor antagonists, NMDA receptor antagonists, sigma-1 receptor inhibitors, histamine H3 antagonists, immunomodulatory agents, immunosuppressive agents, beta-amyloid antibodies, cysteine protease inhibitors, MCP-1 antagonists or an agent selected from the group consisting of natalizumab, fampridine-SR, alemtuzumab, IR 208, NBI 5788/MSP 771 (tiplimotide), paclitaxel, Anergix.MS (AG 284), SH636, CD 271, adapalene, BAY 361677 (interleukin-4), matrix-metalloproteinase-inhibitors, BB 76163, interferon-tau (trophoblastin), and SAIK-MS.

Details for Patent 9,126,987

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2026-11-30
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001		2026-11-30
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	11/14/2014		2026-11-30
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	10/12/2004		2026-11-30
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	11/23/2004		2026-11-30